TrialCardiovascular drugs and therapy2017

MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.

Joannes A A Reijers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.